Home > Name List By other > [4-(4-amino-6, 7-dimethoxyquinazolin-2-yl)piperazin-1-yl]-(oxolan-2-yl)methanone

CAS No 63590-64-7 , [4-(4-amino-6,
7-dimethoxyquinazolin-2-yl)piperazin-1-yl]-(oxolan-2-yl)methanone

  • Name: [4-(4-amino-6,
    7-dimethoxyquinazolin-2-yl)piperazin-1-yl]-(oxolan-2-yl)methanone
  • Synonyms: Fosfomic; Terazosinum [INN-Latin]; Blavin; Vasomet; Hytrin; Terazosine [INN-French];[4-(4-amino-6,
    7-dimethoxyquinazolin-2-yl)piperazin-1-yl]-(oxolan-2-yl)methanone; Flumarc;Terazosine;
  • CAS Registry Number:
  • Density: 1.332 g/cm3
  • Water Solubility: H2O: 25 mg/mL in water
  • Safety Statements: 26
  • Hazard Symbols: Xn: Harmful;
  • Molecular Weight: 387.4329
  • InchiKey: VCKUSRYTPJJLNI-UHFFFAOYSA-N
  • InChI: InChI=1S/C19H25N5O4/c1-26-15-10-12-13(11-16(15)27-2)21-19(22-17(12)20)
    24-7-5-23(6-8-24)18(25)14-4-3-9-28-14/h10-11,14H,3-9H2,1-2H3,(H2,20,21,
    22)
  • Risk Statements: 22
  • Molecular Formula: C19H25N5O4
  • Molecular Structure:CAS No:63590-64-7 [4-(4-amino-6,<br />7-dimethoxyquinazolin-2-yl)piperazin-1-yl]-(oxolan-2-yl)methanone
Search by region :

Select to

63590-64-7 terazosin

Contact Supplier

63590-64-7 terazosin

  • IUPAC NAME-RS)-6,7-dimethoxy-2-[4-(tetrahydrofuran-2-ylcarbonyl)piperazin-1-yl]quinazolin-4-amine MOLECULAR FORMULA-C19H25N5O4 MOLAR MASS-387.433 g/mol
  • India Swapnroop Drugs and Pharmaceuticals [Manufacturer, Trading Company, Distributor/Wholesaler]
  • Tel: 91-240-6641875
  • Fax: 91-240-6641870
  • Address: Harsool aurangabad,maharashtraIndia
Contact Supplier

63590-64-7 Terazosin

Contact Supplier

63590-64-7 Terazosin

  • Terazosin
  • United Kingdom Molekula Ltd [Manufacturer]
  • Tel: +44 1202 863000
  • Fax: +44 1202 863003
  • Address: Technology House Old Forge Road Ferndown Industrial Estate Wimborne Dorset Bh21 7RR null,nullUnited Kingdom
Contact Supplier

63590-64-7 Terazosin

  • Terazosin B41900 63590-64-7
  • China bepharm ltd. null
  • Tel: 86-21-51816456
  • Address: 128 Xiangyin Road, Room C320-321 Yangpu District, Shanghai 200433, China null,nullChina
Contact Supplier

63590-64-7 Terazosin hydrochloride

  • China Pharmasi Chemicals Co.,Ltd null
  • Fax: +86-21-57819315
  • Address: Room 205, Renlesancun50-29,songjiang,shanghai,China null,nullChina
Contact Supplier

63590-64-7 Terazosin

  • China Xingcheng Chempharm Co., Ltd [Manufacturer]
  • Tel: +86-576-88525005/ +86-576-88886292
  • Fax: +86-576-88225056
  • Address: B Area, 10F, Yaoda Mansion, 289, Shifu Road, Taizhou, Zhejiang, China 318000 null,nullChina
Contact Supplier

63590-64-7 Terazosin

  • United States Aceto Corporation [Importer/Exporter]
  • Tel: +1-(516)-627-6000
  • Fax: +1-(516)-627-6093
  • Address: One Hallow Lane, Lake Success, New York 11042-1215, null,nullUnited States
Contact Supplier

63590-64-7 Terazosin

  • China Facus Pharmaceutical Co., Ltd. [Manufacturers]
  • Tel: +86-(574)-6237-8411
  • Fax: +86-(574)-6237-8410
  • Address: 24Fl, Yuanjing Building, Beilun, Ningbo, Zhejiang 315800, Ningbo,ZhejiangChina
Contact Supplier

63590-64-7 Terazosin

  • United States Tecoland Corporation null
  • Tel: +1-(732)-603-9577
  • Fax: +1-(732)-906-1522
  • Address: 100 Menlo Park Drive, Suite 316, Edison, New Jersey 08837-2428, null,nullUnited States
Contact Supplier

Select to

References of [4-(4-amino-6,
7-dimethoxyquinazolin-2-yl)piperazin-1-yl]-(oxolan-2-yl)methanone
Title: Terazosin
CAS Registry Number: 63590-64-7
CAS Name: 1-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-4-[(tetrahydro-2-furanyl)carbonyl]piperazine
Synonyms: 2-[(4-tetrahydro-2-furoyl)-1-piperazinyl]-4-amino-6,7-dimethoxyquinazoline
Molecular Formula: C19H25N5O4
Molecular Weight: 387.43
Percent Composition: C 58.90%, H 6.50%, N 18.08%, O 16.52%
Literature References: a1-Adrenergic blocker related to prazosin, q.v. Prepn: M. Winn et al., DE 2646186; eidem, US 4026894 (both 1977 to Abbott); of the hydrochloride dihydrate: R. Roteman, DE 2831112; idem, US 4251532 (1979, 1981 both to Abbott). HPLC determn in biological fluids: S. E. Patterson, J. Chromatogr. 311, 206 (1984). Toxicity in rats: F. L. Fort et al., Drug Chem. Toxicol. 7, 435 (1984). Clinical study in essential hypertension: P. A. Abraham et al., Pharmacotherapy 5, 285 (1985); in treatment of benign prostatic hyperplasia: H. Lepor et al., J. Urol. 148, 1467 (1992). Symposium on pharmacology, pharmacokinetics, and clinical efficacy in hypertension: Am. J. Med. 80, Suppl. 5B, 1-105 (1986). Comprehensive description: Z. L. Chang, J. F. Bauer, Anal. Profiles Drug Subs. 20, 693-727 (1991). Review of pharmacology and therapeutic efficacy: R. Achari, A. Laddu, J. Clin. Pharmacol. 32, 520-523 (1992).
Properties: Fine, white, odorless crystals, mp 272.6-274°. Soly at 25°C (mg/ml): methanol 33.7; water 29.7; 95% ethanol 4.1; 0.1N HCl 3.8; chloroform 1.2; acetone 0.01. Practically insol in hexane. uv max (0.005% in water): 212, 245, 330 nm (a 65.7, 127.5, 24.0). pKa (0.1N NaOH): 7.1.
Melting point: mp 272.6-274°
pKa: pKa (0.1N NaOH): 7.1
Absorption maximum: uv max (0.005% in water): 212, 245, 330 nm (a 65.7, 127.5, 24.0)
 
Derivative Type: Hydrochloride
Molecular Formula: C19H25N5O4.HCl
Molecular Weight: 423.89
Percent Composition: C 53.84%, H 6.18%, N 16.52%, O 15.10%, Cl 8.36%
Properties: Hygroscopic crystals from isopropyl alc, mp 278-279°. Soly in water: 761.2 mg/ml. LD50 in mice (mg/kg): 259.3 i.v. (Winn).
Melting point: mp 278-279°
Toxicity data: LD50 in mice (mg/kg): 259.3 i.v. (Winn)
 
Derivative Type: Hydrochloride dihydrate
CAS Registry Number: 70024-40-7
Manufacturers' Codes: Abbott 45975
Trademarks: Heitrin (Abbott); Hytracin (Dainabot-Dainippon); Hytrin (Abbott); Hytrinex (Abbott); Itrin (Abbott); Urodie (Abbott); Vasocard (Abbott); Vasomet (Sanko-Nikken); Vicard (Abbott)
Molecular Formula: C19H25N5O4.HCl.2H2O
Molecular Weight: 459.92
Percent Composition: C 49.62%, H 6.57%, N 15.23%, O 20.87%, Cl 7.71%
Properties: mp 271-274°. Soly in water: 24.2 mg/ml. LD50 in male, female rats (mg/kg): 277, 293 i.v. (Fort).
Melting point: mp 271-274°
Toxicity data: LD50 in male, female rats (mg/kg): 277, 293 i.v. (Fort)
 
Therap-Cat: Antihypertensive. In treatment of benign prostatic hyperplasia.
Keywords: a-Adrenergic Blocker; Antihypertensive; Quinazoline Derivatives; Antiprostatic Hypertrophy.